Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy

Antiviral Therapy

Volumn 12, Issue 8, 2007, Pages 1247-1254

  Aurpibul, Linda ^a   Puthanakit, Thanyawee ^a   Lee, Benjamin ^a   Mangklabruks, Ampica ^a   Sirisanthana, Thira ^a   Sirisanthana, Virat ^b  

^a CHIANG MAI UNIVERSITY   (Thailand)

^b Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEVIRAPINE; STAVUDINE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DYSLIPIDEMIA; EVENING DOSAGE; FEMALE; GLUCOSE BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; LIPOATROPHY; LIPODYSTROPHY; LIPOHYPERTROPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; WAIST HIP RATIO;

ADOLESCENT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; LAMIVUDINE; LIPODYSTROPHY; MALE; NEVIRAPINE; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; THAILAND;

EID: 38049009326     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. UNAIDS. 2006 Report on the global AIDS epidemic: Executive Summary/UNAIDS. [Accessed 15 November 2007]. Available from http://www.unaids. org/en/default.asp
2. Puthanakit T, Oberdorfer A, Akarathum N, et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's national access to antiretroviral program. Clin Infect Dis 2005; 41:100-107.
3. Puthanakit T, Aurpibul L, Oberdorfer P, et al. Hospitalization and mortality of HIV-infected children after receiving highly active antiretroviral therapy. Clin Infect Dis 2007; 44:599-604.
4. Puthanakit T, Aurpibul L, Oberdorfer P, et al. Sustained immunologic and virologic efficacy after 4 years of highly active antiretroviral therapy in human immunodeficiency virus-infected children in Thailand. Pediatr Inf Dis J 2007; 26:953-956
5. Carr A, Samaras K, Chisholm DJ, et al. Abnormal fat distribution and use of protease inhibitors. Lancet 1998; 351:1736.
6. Mallon PW, Cooper DA, Carr A. HIV-associated lipodystrophy. HIV Med 2001; 2:166-173.
7. Nolan D, Mallal S. Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms. Antivir Ther 2004; 9:849-863.
8. Babl FE, Regan AM, Pelton SI. Abnormal body-fat distribution in HIV-1-infected children on antiretrovirals. Lancet 1999; 353:1243-1244.
9. Jaquet D, Levine M, Ortega-Rodriguez, et al. Clinical and metabolic presentation of the lipodystrophy syndrome in HIV-infected children. AIDS 2000; 14:2123-2128.
10. +-lymphocyte percentage at baseline and use of protease inhibitors and stavudine. J Acquir Immune Defic Syndr 2001; 27:30-34.
11. Amaya RA, Kozinetz CA, Mcmeans A, Schwarzwald H, Kline MW Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002; 21:405-110.
12. Vigano A, Mora S, Testolin C, et al. Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children. J Acquir immune Defic Syndr 2003; 32:482-489.
13. European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS 2004; 18:1443-1451.
14. Torres AMS, Muniz RM, Madero R, Borque C, Garcia-Miguel MI, Gomez MIDJ. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children. Eur J Pediatr 2005; 164:271-276.
15. Lapphra K, Vanprapar N, Phongsamart W, Chearskul P, Chokephaibulkit K. Dyslipidemia and lipodystrophy in HIV-infected Thai children on highly active antiretroviral therapy (HAART). J Med Assoc Thai 2005; 88:956-966.
16. Beregszaszi M, Dollfus C, Levine M, et al. Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children. J Acquir Immune Defic Syndr 2005; 40:161-168.
17. Hartman K, Verweel G, Groot R, Hartwig NG. Detection of lipoatrophy in human immunodeficiency virus-1-infected children treated with highly active antiretroviral therapy. Pediatr Infect Dis J 2006; 25:427-431.
18. Ene L, Goetghebuer T, Hainaut M, Peltier A, Toppet V, Levy J. Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study. Eur J Pediatr 2007; 166:13-21.
19. Brambilla P, Bricalli D, Sala N, et al. Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy. AIDS 2001; 15:2415-2422.
20. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services. (10 October 2006; pp. 75, Table 7b. Accessed 15 November 2007.) Available from http://www.aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentsGL.pdf
21. Behrens GM, Meyer-Olson D, Stoll M, Schmidt RE. Clinical impact of HIV-related lipodystrophy and metabolic abnormalities on cardiovascular disease. AIDS 2003; 17:S149-S154.
22. Bitnun A, Sochett E, Dick PT, et al. Insulin sensitivity and beta-cell function in protease inhibitor-treated and -naive human immunodeficiency virus-infected children. J Clin Endocrinol Metab 2005; 90:168-174.
23. Centers for Disease Control and Prevention. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Morb Mortal Wkly Rep 1994; 43:1-10.
24. Working group on using weight and height references in evaluating the growth status of Thai children. Manual on using weight and height references in evaluating growth status of Thai children. Bangkok: Department of Health, Ministry of Public Health, 2000.
25. Pruenglampoo S, Kingkeow C, Nimsakul S, et al. Anthropometric indicators among normal nutritional status of school children in Mueang District, Chiang Mai Province. Proceedings of the 2nd Research Conference at Chiang Mai University. 8-10 December 2006, Chiang Mai, Thailand. Abstract P-65.
26. Carr A, Emery S, Law M, Puis R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003; 361:726-735.
27. American Academy of Pediatrics, Committee on Nutrition. Cholesterol in childhood. Pediatrics 1998; 101:141-147.
28. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285:2486-2497.
29. Working group on antiretroviral therapy and medical management of HIV-infected children. Guidelines for the use of antiretroviral agents in pediatric HIV infection, supplement III: adverse drug effects, October 2006. (p.17-22. [Accessed 15 November 2007). Available from http://www.aidsinfo.nih. org
30. Fontas E, Leth F, Sabin CA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004;189:1056-1074.
31. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000; 320:1-6.
32. Leonard EG, McComsey GA. Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival. Infect Dis Clin N Am 2005; 19:713-729.
33. Pujari SN, Dravid A, Naik E, et al. Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in western India. J Acquir Immune Defic Syndr 2005; 39:199-202.
34. Tin EE, Bowonwatanuwong C, Desakorn V, Wilairatana P, Krudsood S, Pitisuttithum P. The efficacy and adverse effects of GPO-vir (stavudine+lamivudine+nevirapine) in treatment-naive adult HIV patients. Southeast Asian J Trop Med Public Health 2005; 36:362-369.
35. Tershekovec AM, Rader DJ. Disorders of lipoprotein metabolism and transport. In Nelson Textbook of Pediatrics. 17th edn. Edited by RE Behrman, RM Kliegman & HB Jenson. Pennsylvania: Elsevier Science 2004; pp. 445-449.
36. Leth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 2004; 1:64-74.